Louisiana's Standing Problem: When State Authority Meets Federal Jurisdiction

The Official Narrative

Louisiana, alongside several other states, has urged the Supreme Court to uphold a lower court order blocking the mailing of abortion medication nationwide. The state argues it has authority to restrict access to mifepristone within its borders and that federal approval of mail-order distribution circumvents state sovereignty. The petition frames this as a matter of states' rights to regulate medical practice and protect health within their jurisdictions—a principle Louisiana contends is under assault by federal administrative overreach.

The claim rests on two foundational assertions: first, that states possess constitutional authority to regulate the practice of medicine within their borders; second, that the FDA's approval of telemedicine abortion and mail-order distribution infringes upon that authority by making state-level restrictions effectively unenforceable.

The Constitutional Mechanism Actually at Work

The Supremacy Clause, Article VI, Clause 2 of the Constitution, establishes that federal law "shall be the supreme Law of the Land." When Congress exercises its enumerated powers—including regulation of interstate commerce under Article I, Section 8—validly enacted federal law preempts conflicting state law. The Federal Food, Drug, and Cosmetic Act (FDCA) of 1938, as amended, delegates to the FDA the authority to determine whether drugs are safe and effective for interstate distribution.

The FDA approved mifepristone in 2000 under a rigorous review process. In 2021 and 2023, the agency modified its Risk Evaluation and Mitigation Strategy (REMS) to permit telemedicine prescribing and mail distribution, citing safety data accumulated over two decades. These modifications were exercises of authority explicitly granted by Congress under the FDCA.

Louisiana's argument encounters a structural problem: Article III standing requirements. To invoke federal judicial power, a plaintiff must demonstrate concrete injury traceable to the defendant's conduct and likely redressable by judicial relief. Lujan v. Defenders of Wildlife (1992) established that generalized grievances or abstract policy disagreements do not confer standing. States may have special standing in certain contexts—particularly when federal action directly injures state sovereignty or proprietary interests—but the threshold remains: specific, particularized injury.

What the Record Shows—and What It Omits

The lower court order Louisiana seeks to uphold was issued in a case brought by anti-abortion medical groups and individual physicians, not states. Those plaintiffs challenged the FDA's approval modifications, arguing the agency failed to adequately consider safety concerns. In April 2024, the Supreme Court unanimously rejected their standing in FDA v. Alliance for Hippocratic Medicine, with Justice Kavanaugh writing that the plaintiffs had not demonstrated they would be required to participate in abortion procedures or suffer concrete harm from mifepristone's availability.

Louisiana's intervention attempts an end-run around that standing defect. The state asserts it suffers injury through increased emergency room visits, administrative costs, and the frustration of its regulatory scheme. But the record omits critical context: mifepristone-related emergency visits are statistically rare (approximately 0.32% of users experience complications requiring medical attention, according to FDA data through 2021), and states routinely bear costs associated with federally approved medical treatments without those costs conferring Article III standing to challenge federal drug approvals.

More fundamentally, Louisiana's brief does not address the mechanism by which a state acquires authority to override a federal agency's determination under a federal statute governing interstate commerce. The FDA's jurisdiction over drug approval is not consultative; states do not possess a constitutional veto over federal determinations of drug safety and efficacy for products moving in interstate commerce.

Mapping the Jurisdictional Gap

The gap between Louisiana's claim and the constitutional architecture is procedural and substantive. Procedurally, the state seeks standing by asserting costs that are indirect consequences of individuals' choices—choices the individuals retain the right to make under federal law. This is precisely the type of generalized grievance the Court rejected in Alliance for Hippocratic Medicine.

Substantively, Louisiana conflates two distinct authorities: the traditional state police power to regulate medical practice and the federal authority to regulate drug approval and interstate distribution. States may regulate who prescribes medication and under what circumstances within their borders, but they cannot nullify a federal determination that a drug is safe and effective for interstate commerce. The distinction is not academic—it defines the boundary between state sovereignty and federal supremacy.

Louisiana's petition seeks a nationwide injunction: an order preventing mifepristone mailing not just in Louisiana but in all fifty states. This reveals the structural overreach. Even if Louisiana could demonstrate standing for an order affecting its own territory, the constitutional mechanics provide no basis for one state to dictate pharmaceutical access in jurisdictions where voters and legislatures have made different policy choices.

The Structural Defect

What emerges is not simply a policy disagreement but a category error about the locus of authority. Louisiana invokes federalism principles to justify a remedy—a nationwide injunction against a federal agency's interstate commerce regulation—that would itself represent an extraordinary expansion of state power beyond anything the Tenth Amendment contemplates.

The omission of any engagement with Alliance for Hippocratic Medicine is not incidental. That unanimous decision established that objection to FDA policy, even when framed as concern for patient safety or professional ethics, does not create Article III standing absent concrete, particularized injury. Louisiana asks the Court to carve out a special state exception without explaining what limiting principle would prevent any state from challenging any federal drug approval that indirectly generates costs or contradicts state policy preferences.

The Accountability Mechanism

The Constitution provides a remedy for states that believe federal agencies exceed their statutory authority: Congress. If the FDA has misapplied the FDCA, the legislative branch retains full authority to amend the statute, narrow the delegation, or override agency action. Louisiana's congressional delegation can introduce legislation, hold hearings, and rally votes.

What Louisiana cannot do—consistent with Article III and the Supremacy Clause—is invoke federal judicial power to enjoin a federal agency's lawful execution of federal law simply because the state disagrees with the policy outcome. The mechanical question is not whether mifepristone should be available by mail. The question is which institution has constitutional authority to make that determination. The answer, under the statutory and constitutional framework actually in force, is the federal agency Congress empowered to make it.